<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04184271</url>
  </required_header>
  <id_info>
    <org_study_id>2016-11-08</org_study_id>
    <nct_id>NCT04184271</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Advantage Arrest</brief_title>
  <official_title>Pharmacokinetics of Advantage Arrest</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Advantage Silver Dental Arrest, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Advantage Silver Dental Arrest, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aim is to characterize the kinetics of silver and fluoride after topical
      application of silver diamine fluoride.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to characterize basic PK parameters (Cmax, t1/2, AUC, and total
      urinary recovery) to contribute to evidence for the safety of Advantage Arrest, consistent
      with Guidance for Industry--Exposure--Response Relationships (April 2003).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Actual">March 31, 2019</completion_date>
  <primary_completion_date type="Actual">September 30, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open label exposure--response study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Observed Fluoride Tmax</measure>
    <time_frame>baseline to 24 hours</time_frame>
    <description>Observed fluoride time to maximum serum concentration in hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Observed Fluoride Cmax</measure>
    <time_frame>baseline to 24 hours</time_frame>
    <description>Observed fluoride maximum serum concentration in ng/mL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Observed Fluoride Baseline-Corrected Cmax</measure>
    <time_frame>baseline to 24 hours</time_frame>
    <description>Observed fluoride baseline-corrected maximum serum concentration in ng/mL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Observed Fluoride t1/2</measure>
    <time_frame>baseline to 24 hours</time_frame>
    <description>Observed fluoride serum elimination half-life in hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Observed Fluoride AUC</measure>
    <time_frame>baseline to 24 hours</time_frame>
    <description>Observed fluoride serum area under the curve in ng-h/mL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Observed Fluoride Urinary Recovery</measure>
    <time_frame>baseline to 24 hours</time_frame>
    <description>24 hour fluoride urinary concentration in ng/mL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Observed Silver t max</measure>
    <time_frame>baseline to 24 hours</time_frame>
    <description>Observed silver time to maximum serum concentration in hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Observed Silver Cmax</measure>
    <time_frame>baseline to 24 hours</time_frame>
    <description>Observed silver maximum serum concentration in ng/mL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Observed Silver Baseline-Corrected Cmax</measure>
    <time_frame>baseline to 24 hours</time_frame>
    <description>Observed silver baseline-corrected maximum serum concentration in ng/mL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Observed Silver t1/2</measure>
    <time_frame>baseline to 24 hours</time_frame>
    <description>Observed silver serum elimination half-life in hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Observed Silver 24 hour urinary concentration</measure>
    <time_frame>baseline to 24 hours</time_frame>
    <description>Observed silver 24-hour urinary concentration in ng/mL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum silver concentrations versus time</measure>
    <time_frame>baseline to 24 hours</time_frame>
    <description>Serum silver concentrations for individual subjects in ng/mL over time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum fluoride concentrations versus time</measure>
    <time_frame>baseline to 24 hours</time_frame>
    <description>Serum fluoride concentrations for individual subjects in ng/mL over time</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Dental Caries</condition>
  <arm_group>
    <arm_group_label>38% silver diamine fluoride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>38% silver diamine fluoride, topical, 1 drop, single application</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>38% silver diamine fluoride</intervention_name>
    <description>Topical application of SDF to teeth</description>
    <arm_group_label>38% silver diamine fluoride</arm_group_label>
    <other_name>Advantage Arrest</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years or older, minimum 20 teeth, healthy, not taking prescription or OTC
             medications

        Exclusion Criteria:

          -  pregnant, weighed less than 50 kg, had oral mucositis or ulcerative lesions, known
             sensitivity to silver or fluoride
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Milgrom, DDS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Washington Institute of Translational Health Sciences</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Lin YS, Rothen ML, Milgrom P. Pharmacokinetics of 38% topical silver diamine fluoride in healthy adult volunteers. J Am Dent Assoc. 2019 Mar;150(3):186-192. doi: 10.1016/j.adaj.2018.10.018.</citation>
    <PMID>30803490</PMID>
  </results_reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 28, 2019</study_first_submitted>
  <study_first_submitted_qc>November 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2019</study_first_posted>
  <last_update_submitted>November 30, 2019</last_update_submitted>
  <last_update_submitted_qc>November 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult</keyword>
  <keyword>fluoride</keyword>
  <keyword>silver</keyword>
  <keyword>silver diamine fluoride</keyword>
  <keyword>pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dental Caries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorides</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>July 7, 2020</submitted>
    <returned>July 20, 2020</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

